Beta Bionics, Inc. Q3 FY2026 earnings call

• Mint Clearance: Received FDA clearance for Mint, the automated insulin delivery (AID) patch pump, with full U.S. commercialization expected in Q1 2027. This marks the fastest time-to-clearance for an AID patch pump concept.
• Capital Raise: Completed a public offering raising approximately $161 million in net proceeds to support Mint manufacturing and strengthen the balance sheet.
• Algorithm Updates: Withdrew the 510(k) submission for 3D Intelligence algorithm at FDA request; resubmission planned for mid-Q4 2026 with additional simulator validation data. No changes to the algorithm itself.
• Pipeline Progress: Completed enrollment in the real-world pivotal trial for type 2 diabetes indication. Initiating pivotal trial for next-generation fully closed loop algorithm (no meal announcements) in adults with type 1 and type 2 diabetes.
• Integrations: Expecting to launch integration with Senseonics' Eversense 365 CGM in Q4 2026.
• Manufacturing: Hiring for four shifts on the initial Mint manufacturing line; CapEx in low-to-mid single-digit millions for Q4 to expand capacity ahead of launch.

Net sales reached a record $35.5 million, representing approximately 30% year-over-year growth. Revenue was driven by an increase in new patient starts and strong retention within the growing pharmacy installed base. Gross margin stood at 57.3%, expanding 179 basis points year-over-year but declining 178 basis points quarter-over-quarter due to unfavorable revenue mix from distributor stocking dynamics of lower-margin supplies.

• Revenue: Increased full-year 2026 revenue guidance to $124–$126 million (from $121–$126 million), reflecting a smaller-than-expected revenue deferral impact from Mint anticipation ($8.5 million vs. prior $10 million estimate).
• Pharmacy Mix: Reiterating expectation that 37%–39% of new patient starts will be reimbursed through the pharmacy channel for the full year.
• Gross Margin: Maintaining full-year gross margin guidance of 58.5%–59.5%, expecting Q4 mix normalization.
• Operating Expenses: Expects modest increase in Q4 operating expenses, primarily driven by higher R&D costs for the fully closed loop pivotal study.
• Capital Expenditures: Expects Q4 CapEx in the low- to mid-single-digit millions.

• Regulatory Delays: Potential delays in FDA clearance for 3D Intelligence and the fully closed loop algorithm could impact product launch timelines.
• Market Adoption Uncertainty: Risk that consumer awareness of Mint is lower than anticipated, potentially affecting early adoption rates despite high preference in surveys.
• Competitive Pressure: Introduction of multiple tubeless/patch pump options in the market may impact share capture versus market expansion.
• Manufacturing Capacity: Initial production constraints may require prioritization of new users over existing iLet conversions during the early launch phase.

Q: Analyst asked if the 3D Intelligence withdrawal indicated algorithm flaws or human factors issues. / A: CEO clarified the withdrawal was purely procedural due to running out of time at the end of the 90-day review period, not because of algorithmic concerns. The FDA requested additional validation data for the simulation tool itself, not the algorithm's output or user interface. They intend to resubmit in mid-Q4 2026 with this extra validation, keeping the same algorithm intact. Clearance later this year remains possible if the agency picks up the file as a continuation.

Q: Analyst questioned whether the lighter-than-expected revenue deferral implied weak interest in Mint compared to iLet. / A: CEO explained that lower deferrals reflect lower consumer awareness rather than lack of interest, noting survey data showed ~90% of current users would prefer Mint. Most patients are not actively tracking Mint's release date, so they continue purchasing iLet. Management expects the deferred demand to convert into significant sales in 2027.

Q: Analyst sought details on the competitive differentiation of the next-generation fully closed loop (FCL) algorithm. / A: CEO distinguished their 'forced FCL' approach, which removes meal announcements entirely, from competitors who maintain hybrid complexity. This design aims to simplify usage for both Type 1 and Type 2 patients, including those in primary care settings where training is difficult. He asserted this architecture offers broader accessibility and potentially lower hypoglycemia risk by reaching underserved populations.

Q: Analyst asked about Mint's gross margin profile and path to accretion in 2027. / A: CFO confirmed Mint will be dilutive to gross margins in 2027 due to initial manufacturing costs. However, he highlighted that design decisions, such as durable components lasting two years and cost-effective disposable parts, position the product to exceed incumbent patch pump margins within three years. Specific 2027 margin guidance was not provided, but models are aligned with sell-side expectations.

Q: Analyst inquired about Mint's insurance coverage trajectory and its impact on the addressable market. / A: CFO stated Mint is classified as a patch pump under Medicare Part D/GPI codes, simplifying reimbursement compared to tubed pumps. They expect ~40% of lives covered at launch, growing to ~50% by year-end 2027. Confidence stems from leveraging existing PBM relationships and market access teams established during the iLet rollout.